Company Overview and News

0
Japan Display looks to road ahead with automotive displays

15h japantimes.co.jp
Japan Display Inc. has been on a rough road for the past four business years, during which the Tokyo-based display manufacturing giant has faced an uphill battle in smartphone panel markets and ended each year with a net loss.
JNNDF 6740 JPDYY

34
UPDATE 2-Mercari chases growth overseas with $1.2 bln IPO, Japan's biggest this year

2018-06-11 reuters
TOKYO (Reuters) - Japanese flea market app operator Mercari Inc’s IPO is raising up to $1.2 billion in the nation’s biggest such share sale so far this year, as the firm seeks to replicate its domestic success overseas, especially in the money-losing U.S. market.
FB 4689 JNNDF 6740 JPDYY YAHOY LN YAHOF

13
Apple set to use only OLED screens for future iPhones: Report

2018-06-08 cnbc
Apple may be planning to use high-end technology in the screens for all of its new iPhone models next year, according to a report from South Korea's Electronic Times.
JNNDF BC94 6740 SMSN JPDYY SMSD

176
Apple's Self-Reliance Strategy Hurts Chip Suppliers Most

2018-06-01 zacks
Apple’s (AAPL - Free Report) strategy of becoming self-reliant has had a detrimental effect on suppliers like Dialog Semiconductor (DLGNF - Free Report) . The iPhone-maker recently lowered its order for power-management chips (PMICs), of which Dialog is the primary supplier, by almost 30%. Apple’s decision to multi-source PMIC chips for one of its three new iPhone models, set to release in 2018, is expected to hurt Dialog’s top-line by 5%.
QRVO JNNDF AAPL CRUS 6740 DLGNF JPDYY INTC

240
Apple Switch to an All OLED iPhone Lineup Unlikely by 2019 - Bloomberg

2018-05-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK OLED GSC GS.PRICL TFG BC94 GS.PRB SMSN GS.PRA JPDYY GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD JNNDF GS.PRC AAPL 6740 GJS GS.PRN SMSD GS.PRK

240
Apple switch to all OLED iPhone lineup seen unlikely by 2019

2018-05-30 livemint
Tokyo: Analysts are pouring cold water on a report that Apple Inc. plans to use next-generation organic light emitting diode panels, or OLED, screens for all of its new iPhone models next year.
JBK OLED GSC GS.PRICL TFG BC94 GS.PRB SMSN GS.PRA JPDYY GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD JNNDF GS.PRC AAPL 6740 GJS GS.PRN SMSD GS.PRK

156
Apple Inc. (AAPL) Likely to Adopt OLED Technology in 2019 iPhone Models

2018-05-29 investorplace
Apple Inc. (NASDAQ:AAPL) is planning to use organic light-emitting diode (OLED) panels in all three new iPhone models planned for next year, reports South Korea’s Electronic Times.
JNNDF AAPL 6740 JPDYY

278
Apple Likely to Adopt OLED Technology in 2019 iPhone Models

2018-05-29 zacks
Apple (AAPL - Free Report) is planning to use organic light-emitting diode (OLED) panels in all three new iPhone models planned for next year, reports South Korea's Electronic Times. We note that for 2018, two out of the three iPhone models — a 5.8-inch second-generation iPhone X and a larger 6.5-inch iPhone X Plus — are expected to offer OLED displays. The low-cost third one is likely to be a 6.1 inch LCD (liquid crystal display) variant.
HRL MU JNNDF AAPL WDC 6740 JPDYY RHT

0
Asian Markets: Credit Risks in China, Nikkei Pressured by the Yen

2018-05-29 marketrealist
Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.
JNNDF 6740 JPDYY

156
Tokyo stocks slip on yen’s ascent

2018-05-29 japantimes.co.jp
The Nikkei 225 average lost 122.66 points, or 0.55 percent, to close at 22,358.43 after gaining 30.30 points on Monday.
TKCBY JNNDF AAPL 6740 JPDYY

157
Nikkei hits 1-month low as cyclicals falter on growth worries

2018-05-29 reuters
TOKYO, May 29 (Reuters) - Japanese shares fell to one-month lows on Tuesday, with investors selling cyclical shares as concerns over European politics added to the list of reasons to be cautious about the global economic outlook.
NIJPF TKCBY JNNDF AAPL 6740 JPDYY

156
Nikkei hits 1-month low on global growth worries

2018-05-29 thehindubusinessline
The Topix fell as much as 0.7 per cent to as low as 1,758.84, its lowest level since late April. The Nikkei average dropped 0.7 per cent to 22,324. - Reuters
JUSTDIAL 535648 NIJPF TKCBY JNNDF AAPL 6740 JPDYY JSTQY

165
Apple said to have chosen OLED for new iPhones; Japan Display shares plunge - Channel NewsAsia

2018-05-29 channelnewsasia
Apple Inc has decided to use OLED screens in all three new iPhone models planned for next year, according to South Korea's Electronic Times - a report that sent shares in Japan Display tumbling 10 percent.
6501 JNNDF AAPL 6740 JPDYY SNE SNEJF HTHIY

156
Nikkei hits 1-month low on global growth worries

2018-05-29 reuters
TOKYO, May 29 (Reuters) - Japanese shares fell to one-month lows on Tuesday with investors selling cyclical shares as concerns over European politics added to the list of reasons to be cautious about the global economic outlook.
NIJPF TKCBY JNNDF AAPL 6740 JPDYY

169
IPhone Screen Makers Fall on Report of Apple OLED Shift in 2019 - Bloomberg

2018-05-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JNNDF AAPL BC94 6740 SMSN JPDYY SMSD

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

20h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 471054106